1. Home
  2. BEAM vs FG Comparison

BEAM vs FG Comparison

Compare BEAM & FG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Beam Therapeutics Inc.

BEAM

Beam Therapeutics Inc.

N/A

Current Price

$26.08

Market Cap

2.7B

Sector

Health Care

ML Signal

N/A

Logo F&G Annuities & Life Inc.

FG

F&G Annuities & Life Inc.

N/A

Current Price

$21.08

Market Cap

3.2B

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
BEAM
FG
Founded
2017
1959
Country
United States
United States
Employees
N/A
1338
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Life Insurance
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
2.7B
3.2B
IPO Year
2019
N/A

Fundamental Metrics

Financial Performance
Metric
BEAM
FG
Price
$26.08
$21.08
Analyst Decision
Buy
Hold
Analyst Count
16
1
Target Price
$49.13
$35.00
AVG Volume (30 Days)
1.7M
464.4K
Earning Date
05-15-2026
01-01-0001
Dividend Yield
N/A
4.54%
EPS Growth
82.31
N/A
EPS
N/A
N/A
Revenue
$24,000.00
N/A
Revenue This Year
N/A
$7.94
Revenue Next Year
$35.80
$5.51
P/E Ratio
N/A
$8.41
Revenue Growth
33.33
N/A
52 Week Low
$13.53
$21.38
52 Week High
$36.44
$42.84

Technical Indicators

Market Signals
Indicator
BEAM
FG
Relative Strength Index (RSI) 43.87 26.03
Support Level $23.84 N/A
Resistance Level $29.06 $29.63
Average True Range (ATR) 1.96 1.18
MACD -0.19 -0.15
Stochastic Oscillator 14.79 4.11

Price Performance

Historical Comparison
BEAM
FG

About BEAM Beam Therapeutics Inc.

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.

About FG F&G Annuities & Life Inc.

F&G Annuities & Life Inc is a provider of insurance solutions serving retail annuity and life customers as well as institutional clients. Through its insurance subsidiaries, including FGL Insurance and Fidelity & Guaranty Life Insurance Company of New York it markets a broad portfolio of deferred annuities (fixed indexed annuities (FIAs) and multi-year guarantee annuities (MYGAs) or other fixed rate annuities), immediate annuities, indexed universal life (IUL) insurance, funding agreements through funding agreement-backed notes (FABN) issuances and the Federal Home Loan Bank of Atlanta (FHLB)), and pension risk transfer (PRT) solutions.

Share on Social Networks: